Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Moving towards the pan-European unification of Multiple Sclerosis Nurses: a consensus paper.
Subclinical CNS Inflammation as Response to a Myelin Antigen in Humanized Mice.
Leber's hereditary optic neuropathy associated with multiple sclerosis: Harding's syndrome.
Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate.
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis.
CHMP assessment report for Sovrima (International nonproprietary name: idebenone)
Long-term effects of dalfampridine in patients with multiple sclerosis.
Neuroenhancement through cognitive training and anodal tDCS in multiple sclerosis.
Relationships between retinal axonal and neuronal measures and global central nervous system pathology in multiple sclerosis.
Stress and hypothalamic-pituitary-adrenal axis function in experimental autoimmune encephalomyelitis and multiple sclerosis - a review.
Changes in phospholipid composition of the spinal cord in rabbits with allergic encephalomyelitis as an experimental model of multiple sclerosis.
Epstein-Barr virus in the multiple sclerosis brain: a controversial issue--report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria.
Clinical overview of the seizure risk of dalfampridine.
The Many Facets of Cell Injury: Angiogenesis to Autophagy.
Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis.
Targeted ablation of oligodendrocytes induces axonal pathology independent of overt demyelination.
Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
22nd Meeting of European Neurological Society
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
"Undiagnosing" multiple sclerosis: The challenge of misdiagnosis in MS.
Galectin-1 for neuroprotection?
Keystone Symposium on Growing to Extremes: Cell Biology and Pathology of Axons
Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity.
VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells.

Pages